Date: 2013-05-02
Type of information:
phase: 3
Announcement:
Company: Ferring Pharmaceuticals (Switzerland)
Product: elobixibat
Action mechanism: Elobixibat is a first-in-class compound with a novel physiological mechanism of action. It acts locally in the gut with minimal systemic exposure to enhance the amount of luminal bile acids in the colon by a partial inhibition of the Ileal Bile Acid Transporter (IBAT). This increases colonic fluid secretion and motility.
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: * On May 2, 2013, Ferring Pharmaceuticals has announced it has initiated enrolment of patients in two phase III clinical trials of elobixibat for the treatment of chronic idiopathic constipation (CIC). The two studies, Echo 1 and Echo 2, will be conducted at close to 200 sites worldwide and will enrol nearly 1700 patients. The studies aim to demonstrate the efficacy and safety of repeated daily doses of elobixibat against placebo over a period of up to 26 weeks. Ferring acquired the global marketing rights for elobixibat, excluding Japan and a small number of Asian markets, from Albireo AB in 2012.
